Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer

Despite recent advances in treatment, breast cancer remains the second-most common cause of cancer death among American women. A greater understanding of the molecular characteristics of breast tumors could ultimately lead to improved tumor-targeted treatment options, particularly for subsets of bre...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosco, Emily E., Christie, R. James, Carrasco, Rosa, Sabol, Darrin, Zha, Jiping, DaCosta, Karma, Brown, Lee, Kennedy, Maureen, Meekin, John, Phipps, Sandrina, Ayriss, Joanne, Du, Qun, Bezabeh, Binyam, Chowdhury, Partha, Breen, Shannon, Chen, Cui, Reed, Molly, Hinrichs, MaryJane, Zhong, Haihong, Xiao, Zhan, Dixit, Rakesh, Herbst, Ronald, Tice, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955426/
https://www.ncbi.nlm.nih.gov/pubmed/29796165
http://dx.doi.org/10.18632/oncotarget.25160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955426/
https://www.ncbi.nlm.nih.gov/pubmed/29796165
http://dx.doi.org/10.18632/oncotarget.25160

Ejemplares similares